The effect of ZAP-70 expression on disease progression in early-stage (Binet A) B-CLL patients
Trakya Universitesi Tip Fakultesi Dergisi, cilt.26, sa.4, ss.317-321, 2009 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 26 Sayı: 4
- Basım Tarihi: 2009
- Dergi Adı: Trakya Universitesi Tip Fakultesi Dergisi
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.317-321
- Anahtar Kelimeler: Chronic lymphocytic leukemia, ZAP-70, prognosis
- Sağlık Bilimleri Üniversitesi Adresli: Evet
Özet
Objectives: Chronic lymphocytic leukemia (CLL) is a heterogeneous disease with various clinical findings. Prognostic markers predicting the clinical outcome in early-stage CLL would play a major role in disease management. Various studies have shown that zeta-associated protein 70 (ZAP-70) provides significant prognostic information. This retrospective, single-centre study evaluates the effect of ZAP-70 on disease progression in early-stage B-CLL. Patients and Methods: Fifty early-stage patients with a median age of 66 years (range 47-86 years) were enrolled in this study. ZAP-70 expression was measured in peripheral blood samples using flow cytometry. Cut-off value for ZAP-70 positivity was set at 20%. Results: Treatment had to be initiated in 21 of the 50 patients within a median of 42 months. The median time to initial treatment was 24 months. Twelve of the 50 patients (24%) were ZAP-70 positive. Ten of the 12 patients (83%) in the ZAP(+) group and 11 of the 38 patients (29%) in the ZAP(-) group required treatment on follow-up. The median treatment-free interval in ZAP(+) and ZAP(-) groups were 25 and 72 months, respectively (p=0.0001). Conclusion: ZAP-70 provides significant prognostic information and predicts treatment requirement in early-stage B-CLL patients. Ongoing studies will highlight the need for a different management policy of ZAP-70(+) early-stage CLL. © Medical Journal of Trakya University. Published by Ekin Medical Publishing. All rights reserved.